CRISPR-Cas9 Mechanism: Adaptive Immunity vs Genetic Engineering

Added:

The Imprecision of Double-Strand Breaks and the Rise of DSB-Free Editing

While traditional CRISPR-Cas9 relies on generating targeted double-strand breaks (DSBs) to enable genetic engineering, a major counter-perspective challenges the 'precision' of this approach. Opponents and newer research highlight that cellular repair of DSBs via pathways like Non-Homologous End Joining (NHEJ) is inherently stochastic and error-prone, frequently resulting in unintended insertions, deletions, large-scale genomic deletions, or chromosomal translocations. Furthermore, forcing DSBs can trigger a p53-mediated DNA damage response, leading to high cellular toxicity or the selective survival of p53-deficient (and potentially oncogenic) cells. This critical limitation has driven a paradigm shift toward 'DSB-free' technologies, such as base editing and prime editing. These alternative systems allow for highly precise single-nucleotide transitions or direct sequence search-and-replace actions without severing the DNA backbone, challenging the foundational assumption that DSB-induction is the optimal method for safe and predictable genome modification.

The structure of DNA and RNA, including complementary base pairing rules which dictate how guide RNA binds to target genomic sites.
The Central Dogma of Molecular Biology, specifically the transcription of DNA into RNA and the translation of RNA into proteins.
Endogenous DNA repair pathways in eukaryotic cells, specifically Non-Homologous End Joining (NHEJ) and Homology-Directed Repair (HDR).
Basic bacterial genetics and the concept of bacteriophages (viruses that infect bacteria) as a threat to bacterial survival.
Next-generation genome editing technologies, such as Base Editors and Prime Editors, which modify single nucleotides without inducing double-strand breaks.
Methods for identifying and minimizing off-target cleavage events, including the use of engineered high-fidelity Cas9 variants.
The current landscape of clinical trials and therapeutic applications of CRISPR, such as ex vivo treatments for sickle cell disease.
The bioethical and regulatory challenges associated with heritable human germline editing versus non-heritable somatic gene therapy.
40.3K views496likes14:33@elliotnicholson5117Original Release: 2015-03-01

The CRISPR-Cas9 system in Streptococcus pyogenes functions as an adaptive immune system where bacteria integrate viral genome fragments into their CRISPR locus, transcribe these into CR RNAs that guide Cas9 enzymes to recognize and cut matching viral DNA sequences, creating double-strand breaks that destroy the virus; this same mechanism can be harnessed for genetic engineering by designing custom CR RNAs to target specific DNA sequences for precise genome editing.